Kiadis Pharma N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 mei 2016 - 06:59
Statutaire naam
Kiadis Pharma N.V.
Titel
Kiadis Pharma presents multiple sets of data at the International Society for Cellular Therapy (ISCT) 2016 Annual Meeting
Bericht
~ New research results presented on retention of potential cancer killing T-cells
in lead product ATIR101™ ~
Amsterdam, The Netherlands, May 18, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that four abstracts have been accepted for presentation at the International Society for Cellular Therapy (ISCT) 2016 Annual Meeting on May 25-28, 2016 in Singapore.
These abstracts provide key clinical data on Kiadis Pharma’s lead product ATIR101™ and on the ATIR101™ development program through one oral presentation and three poster presentations. One of the three poster presentations shows research results on the retention of potential cancer killing T-cells from the donor in ATIR101™ that could eliminate residual cancer cells in a transplanted patient and help prevent relapse of blood cancer, known as the Graft-versus-Leukemia (GVL) effect. The abstract selected for oral presentation is entitled: “Phase II clinical trial of Allodepleted T-cell Immunotherapy (ATIR101) post-transplant results in decreased transplant related mortality and improved survival in acute leukemia patients undergoing T-depleted haploidentical stem cell transplantation” and will be delivered in Room 331 on Friday, May 27, 2016 between 10:45 and 12:15 SGT by Dr. Denis-Claude Roy, Professor of Medicine at the University of Montreal and principal investigator for Kiadis Pharma’s ongoing single-dose Phase II clinical trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™.
In addition, Jurjen Velthuis, the Company’s Vice-President CMC, will give a presentation on ‘Defining critical process parameters’ during the Session “Quality and Operations Track 5 - CMC Process Characterization and Parameters”. This presentation will be delivered in Room 330 on Friday, May 27, 2016
Gerelateerde downloads
Datum laatste update: 29 april 2025